4th Quarter - Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

Firm
Client
Income
—
Expenses
$189,480
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 19, 2012 $189,480 Replaced
4th Quarter - Amendment (this page) Jan 23, 2015 $189,480 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

LobbyistCovered position, as disclosed
ANNE CASSITY —
JOHN M COSTER —
SHAWN FRIESEN New Legislative Director, House of Representives
ADNAN JALIL —
DAVID SANDERS —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); Agency for Healthcare Research & Quality (AHRQ); SENATE; Food & Drug Administration (FDA); Government Accountability Office (GAO); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Office of Personnel Management (OPM); Defense, Dept of (DOD); Federal Trade Commission (FTC)

Bills named: S. 296 (112th), S. 1253 (112th), S. 1867 (112th), H.R. 891 (112th), H.R. 1946 (112th), H.R. 979 (112th), S. 882 (112th), S. 1699 (112th), H.R. 1316 (112th), S. 319 (112th), S. 1356 (112th), H.R. 866 (112th), H.R. 1540 (112th), H.R. 1971 (112th), H.R. 1839 (112th), S. 1058 (112th), S. 1002 (112th), S. 513 (112th), H.R. 1936 (112th), S. 1560 (112th), S. 1251 (112th), H.R. 1041 (112th), H.R. 1409 (112th), S. 274 (112th), S. 2002 (112th), H.R. 2939 (112th), S. 507 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.